Archemix, a Cambridge, MA-based biotech startup developing aptamer drugs, reports that Kenneth Bate will replace Duncan Higgons as CEO of the company. Higgons, who had become chief executive of the firm in January, is taking a job with another private biotech firm, according to Archemix. Bate was most recently president and CEO of Lexington, MA-based drug developer NitroMed, which walked away from a proposed merger with Archemix early this year.
Author: Ryan McBride
Ryan is an award-winning business journalist who contributes to our life sciences and technology coverage. He was previously a staff writer for Mass High Tech, a Boston business and technology newspaper, where he and his colleagues won a national business journalism award from the Society of American Business Editors and Writers in 2008. In recent years, he has made regular TV appearances on New England Cable News.
Prior to MHT, Ryan covered the life sciences, technology, and energy sectors for Providence Business News. He graduated with honors from the University of Rhode Island in 2001 with a bachelor’s degree in communications. When he’s not chasing down news, Ryan enjoys mountain biking and skiing in his home state of Vermont.
View all posts by Ryan McBride
